Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli

Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli

We conducted a prospective, randomized, open-label trial to evaluate the efficacy and tolerability of cefepime in the treatment of osteomyelitis caused by Gram-negative bacilli. Hospitalized patients with diagnosis of osteomyelitis due to Gram-negative bacilli susceptible to cefepime were elegible f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista española de quimioterapia 2000-12, Vol.13 (4), p.366-373
Hauptverfasser: Barberán, J, Gomis, M, Sánchez, B, Hernández-Salván, J, García Del Salto, L, Carroquino, G, González, F, Hernández, M
Format: Artikel
Sprache:spa
Schlagworte:
Acute Disease
Adult
Aged
Aged, 80 and over
Cephalosporins - therapeutic use
Chronic Disease
Female
Gram-Negative Bacterial Infections - drug therapy
Gram-Negative Bacterial Infections - microbiology
Humans
Male
Middle Aged
Osteomyelitis - drug therapy
Osteomyelitis - microbiology
Patient Selection
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We conducted a prospective, randomized, open-label trial to evaluate the efficacy and tolerability of cefepime in the treatment of osteomyelitis caused by Gram-negative bacilli. Hospitalized patients with diagnosis of osteomyelitis due to Gram-negative bacilli susceptible to cefepime were elegible for enrollment. Cefepime was administered intravenously or intramuscularly (2 g every 8 or 12 hours). Microorganisms were considered susceptible to cefepime when the MIC was
ISSN:0214-3429